Skip to Content
Global News Select

Gilead Sciences Swings to 2Q Profit as Revenue Soars 21%

By Kimberly Chin


Gilead Sciences Inc. swung to a profit in the second quarter as revenue increased 21% driven by higher demand for therapies such as remdesivir, Biktarvy and its hepatitis C virus products as well as stronger demand for Trodelvy and Tecartus in the U.S.

The biopharmaceutical company's net profit was $1.52 billion, compared with a loss of $3.34 billion a year earlier. Earnings were $1.21 a share for the quarter, compared with a loss of $2.66 a shaer a year ago. Excluding special items, Gilead posted an adjusted profit of $1.87 a share. Analysts polled by FactSet were expecting adjusted earnings of $1.74 a share.

Total revenue rose to $6.22 billion from $5.14 billion in the year-earlier period. Analysts estimated $6.08 billion in revenue. Sales of its flagship HIV therapy Biktarvy increased by 24% from the prior year.


Write to Kimberly Chin at


(END) Dow Jones Newswires

July 29, 2021 16:29 ET (20:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.